Recreational use of HIV antiretroviral drug linked to its psychoactivity
2013-04-21
(Press-News.org) BOSTON — More than 1 in 270 people in the US are living with HIV and every 9.5 minutes someone is else is infected. The economic cost estimates associated with HIV/AIDS exceed 36 billion dollars a year. The development of effective drug treatments have allowed people with HIV to live longer with federal health officials now predicting that by 2015 one-half of the population with HIV in the US will be older than 50.
Efavirenz (tradenames: Sustiva®, Stocrin®) is an antiretroviral (ARV) drug commonly used to treat HIV. Its popularity as a medication, alone or more commonly in combination with other HIV medications (tradename: Atripla®), is due to its superior effectiveness in suppressing replication of the virus that causes AIDS. Though highly effective, a standard dose of efavirenz is known to carry a risk of side effects that include adverse neuropsychiatric complications such as depression, anxiety, sleep disturbances, impaired concentration, aggressive behavior, night terrors, hallucinations, paranoia, psychosis and delusions. However the question remains as to why these side effects occur. Recent anecdotal reports of the recreational use of efavirenz provided some clues.
Dr. John A. Schetz at the University of North Texas Health Science Center in Fort Worth, Texas, utilizes a mechanistic approach to solving problems and answering questions of importance to society. As a neuropharmacologist working to discover and develop new drugs for the treatment of neurological and psychiatric disorders, his experience and intuition helped solve the mystery as to why efavirenz, when taken as prescribed, can cause adverse psychiatric events, as well as why there are reports of efavirenz being diverted for recreational use. The later practice could encourage the emergence of ARV-resistant HIV strains by educating the HIV virus.
Dr. Schetz's interest was sparked by a network news report covering the topic of ARV abuse in South Africa. The report described how pills used to treat HIV were being crushed and the powder smoked for its psychoactive effects. Though there were no scientific studies on the topic, Dr. Schetz was aware of studies describing neuropsychiatric side effects in HIV patients taking the medication as prescribed, as well as case reports of sudden onset adverse psychiatric events in patients with no history of mental illness. However, research study results suggested that the later patient population were genetically predisposed because they have less effective variants of the enzyme primarily responsible for metabolizing efavirenz, leading to much slower than expected breakdown of efavirenz, and consequently higher than expected levels of drug in the body. Dr. Schetz initiated his investigation with molecular profiling of the receptor pharmacology of efavirenz which lead to the pinpointing of interactions with multiple established sites of action for other known drugs of abuse. He and a number of his colleagues worked together to achieve a pre-clinical understanding of the psychoactivity induced by efavirenz that may help explain reports both of its adverse neuropsychiatric side effects in HIV patients and of its diversion for recreational use.
Dr. Schetz's work is the first ever study of the mechanisms of efavirenz's psychopharmacology and these new findings will help stimulate interest to support additional research related to the mechanism of ARV side effects and abuse potential. This would help translate the pre-clinical findings into preventative measures addressing HIV medication-induced adverse side effects in patients living with HIV. Additionally, preventative strategies would improve patient adherence and quality of life, reduce the potential risk for the emergence of HIV drug resistant strains, and could prevent diversion of HIV medication for illicit use."
His findings will be presented April 21, 2012 during Experimental Biology 2013 in Boston, MA.
###
To request an interview with Dr. Schetz, please contact Jim Bernstein at the contact information listed above.
About Experimental Biology 2013
Experimental Biology's mission is to share the newest scientific concepts and research findings shaping future and current clinical advances – and to give scientists and clinicians an unparalleled opportunity to hear from colleagues working on similar biomedical problems using different disciplines. With six sponsoring societies and another 20 U.S. and international guest societies, the annual meeting brings together scientists from throughout the United States and the world, representing dozens of scientific areas, from laboratory to translational to clinical research. The meeting also offers a wide spectrum of professional development sessions.
About the American Society for Pharmacology and Experimental Therapeutics
ASPET is a 5,100 member scientific society whose members conduct basic and clinical pharmacological research within the academic, industrial and government sectors. Our members discover and develop new medicines and therapeutic agents that fight existing and emerging diseases, as well as increase our knowledge regarding how therapeutics affects humans.
END
ELSE PRESS RELEASES FROM THIS DATE:
2013-04-21
BOSTON — Depression is the leading cause of disability with more than 350 million people globally affected by this disease. In addition to debilitating consequences on mental health, depression predisposes an individual to physiological disease such as heart disease, and conversely heart disease increases the risk of depression. According to the World Health Organization by the year 2020 heart disease and depression will be the number one and number two leading causes of disability in developed countries. While the co-occurrence of these disorders is well recognized, an ...
2013-04-21
Geneva, Switzerland: Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found. [1]
Common cancers such as breast, oesophagus, lung, and Hodgkin's lymphoma are frequently treated with radiotherapy, but the radiation dose that can be given safely is limited by the sensitivity of the health lung tissue which is also irradiated.
The lung is a particularly complex ...
2013-04-21
Middle school students from rural Maine will present a poster at the Experimental Biology 2013 conference detailing how their involvement with the Aspirnaut science-outreach program led to them becoming active scientific researchers.
Students from the Dedham School in Dedham, Maine, were participants in the Aspirnaut program (http://www.aspirnaut.org), a science-outreach program started at Vanderbilt University, in which scientists engage with middle- and high-school students through videoconferencing. Showing a great interest in the research that was being demoed by ...
2013-04-21
Geneva, Switzerland: Intensity modulated radiotherapy (IMRT) gives better results than standard radiotherapy in patients with early breast cancer, according to results from a randomised trial presented today (Sunday) to the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO). IMRT is an advanced, high-precision form of radiotherapy that can deliver an even dose of radiation, thus reducing the cosmetic problems that can often occur after breast radiotherapy.
"We believe that this study, the largest prospective trial in the world to test breast IMRT ...
2013-04-21
Lisa B. Overton is opening up and telling the world about her life as the child of a forbidden love affair. This moving story details her experience growing up as the child of a Roman Catholic priest and an ex-nun who entered into a 30+ year clandestine love affair.
She tells the poignant story of her childhood and how she survived loneliness, shame and hypocrisy in her parents' painful and secretive shadow and how she eventually forgave them both. She never knew who her father was until finally, on her mother's death bed Lisa asked, "Was Uncle my father?" ...
2013-04-21
Brene Brown will be the featured speaker at the University of Houston Graduate College of Social Work (GCSW) inaugural scholarship luncheon, "Daring to Soar," at 11:30 a.m., Wednesday, May 8 at the Houston Country Club.
For more than a decade, Brown has been researching and writing about shame, vulnerability, courage and compassion in her role as a research professor at the UH GCSW. Her latest milestone was a two-episode appearance with celebrated talk show host Oprah Winfrey to discuss Brown's new book, "Daring Greatly," which made its way onto ...
2013-04-21
On Monday, April 29th 2013 the 14th annual Newport Beach Film Festival will present its Australian Spotlight, an evening celebration of Australian cinema and culture. The event will feature the West Coast Premiere of the highly anticipated film, Drift, followed by a festive post screening gala.
Drift is an action-packed ride that reflects the dynamic surf culture and spirit that is shared by Austrialia and southern Califoria. The film, based on a true story, follows two brothers (Absolut Vodka and Stella Artois Beer, 10 top Orange County restaurants serving signature ...
2013-04-21
Dallas is recognizing Architecture Month in April with a challenge to architects, design professionals and amateur urbanites around the world to share ideas and devise solutions for one of the city's oldest and most vexing development hurdles, according to guests on the most-recent segment of the KRLD 1080 AM "Pulse of the City" radio show, sponsored by the Dallas law firm Munck Wilson Mandala.
The Connected City Design Challenge seeks new strategies for connecting and unifying Downtown Dallas with the extensive development underway along the Trinity River. ...
2013-04-21
On Tuesday, April 16, 2013, Mr, Lichtenstein's firm obtained a 2.1 Million Dollar verdict in a Brachial Plexus/ Erb's Palsy case tried in Cooperstown, New York, Brandenburg v. Bassett Hospital.
After prosecuting the case for many years, Mr. Lichtenstein retained Christina M. Sonsire, a highly gifted medical malpractice lawyer in Elimria New York, as trial counsel As Ms. Sonsire stated that "The tremendous outcome of this trial was the result of a true team effort. She noted that Mr. Lichtenstein was involved in every step of the trial process and that his "depth ...
2013-04-21
After an extensive absence from the music industry as promoter of best-selling gospel-jazz recording artist and ex-husband, Ben Tankard and gospel diva, Yolanda Adams and others, Ms. Tankard-Nichols chose to keep a low profile by using the name Benita Savage Nichols to keep in touch with her family, friends, and associates in the gospel music industry and film biz.
According to Ms. Tankard-Nichols, the organization exists for the healing, restoration, and salvation of God's people. She states, "We are a catalyst for end time Revival throughout the Nations of the ...
LAST 30 PRESS RELEASES:
[Press-News.org] Recreational use of HIV antiretroviral drug linked to its psychoactivity
